Pharmacy Health Immune Support Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacy health immune support

soul pattinson manufacturing pty ltd - allium sativum, quantity: 166.67 mg (equivalent: allium sativum, qty 2 g); ascorbic acid, quantity: 50 mg; sambucus nigra, quantity: 28.57 mg (equivalent: sambucus nigra, qty 200 mg); olea europaea, quantity: 200 mg (equivalent: olea europaea, qty 3.6 g); echinacea purpurea, quantity: 22.22 mg (equivalent: echinacea purpurea, qty 1 g); zinc citrate dihydrate, quantity: 15.56 mg (equivalent: zinc, qty 5 mg); handroanthus impetiginosus, quantity: 50 mg (equivalent: handroanthus impetiginosus, qty 200 mg) - capsule, hard - excipient ingredients: maltodextrin; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; traditionally used in western herbal medicine to sudorific/diaphoretic/enhance/promote sweating/perspiration ; maintain/support general health and wellbeing ; maintain/support immune system health ; maintain/support healthy immune system function ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; traditionally used in western herbal medicine to expectorant/clear respiratory tract mucous ; traditionally used in western herbal medicine to relieve symptoms of mild upper respiratory tract infections ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of common cold ; maintain/support wound healing

Marbofloxacin support pharma 40 mg/ml solution for injection for pigs Ireland - English - HPRA (Health Products Regulatory Authority)

marbofloxacin support pharma 40 mg/ml solution for injection for pigs

support pharma, s.l. - marbofloxacin - solution for injection - 40 mg/ml - antibacterial - porcine

Docetaxel Teva Pharma European Union - English - EMA (European Medicines Agency)

docetaxel teva pharma

teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel teva pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.non-small-cell lung cancerdocetaxel teva pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel teva pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel teva pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Pioglitazone Teva Pharma European Union - English - EMA (European Medicines Agency)

pioglitazone teva pharma

teva pharma b.v. - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,

T-SUPPORT MAX capsule United States - English - NLM (National Library of Medicine)

t-support max capsule

tmig inc. - fenamiphos (unii: h4no3l2hbe) (pyridoxine - unii:kv2jz1bi6z), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), selenium (unii: h6241uj22b) (selenium - unii:h6241uj22b), chromium (unii: 0r0008q3jb) (chromium - unii:0r0008q3jb), zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - fenamiphos 100 mg - t-support max is indicated for the clinical dietary management of the individuals with thyroid conditions. hyperthyroidism hyperthyroidism the name given to overproduction of thyrozine, causes extreme nervousness and irritability, increased heart rate and blood pressure, and weight loss. underproduction of thyrozine, or hypothyroidism, results in dry skin, brittle nails, and a lack of energy in adults. goiter, which is actually an enlarged thyroid, is a sign of thyroid insufficiency. in infants, hypothyroidism can be devastating, inhibiting physical development and causing irreversible mental retardation. hypothyroidism hypothyroidism is a condition in which the thyroid gland fails to function adequately, resulting in reduced levels of thyroid hormone in the body. cretinism is a type of hypothyroidism that occurs at birth and results in stunted physical growth and mental development. severe hypothyroidism is called myxedema. interactions with drugs before using this product, tell your doctor or pharmacist

MAYNE PHARMA ERYTHROMYCIN erythromycin 250mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma erythromycin erythromycin 250mg capsule bottle

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: povidone; monobasic potassium phosphate; lactose monohydrate; gelatin; carbon black; sunset yellow fcf; shellac; indigo carmine; purified water; cellacefate; erythrosine; diethyl phthalate - mayne pharma erythromycin is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx

DEXAMETHASONE KERN PHARMA Israel - English - Ministry of Health

dexamethasone kern pharma

mbi pharma ltd., israel - dexamethasone phosphate ( as sodium phosphate ) - solution for injection / infusion - dexamethasone phosphate ( as sodium phosphate ) 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

Pharmacy Health Men's Mega Multivitamin Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacy health men's mega multivitamin

soul pattinson manufacturing pty ltd - panax ginseng, quantity: 5 mg (equivalent: panax ginseng, qty 50 mg); manganese amino acid chelate, quantity: 5 mg (equivalent: manganese, qty 1 mg); zinc amino acid chelate, quantity: 75 mg (equivalent: zinc, qty 15 mg); ferrous fumarate, quantity: 15.2 mg (equivalent: iron, qty 5 mg); nicotinamide, quantity: 75 mg; calcium pantothenate, quantity: 75 mg (equivalent: pantothenic acid, qty 68.7 mg); colecalciferol, quantity: 0.0125 mg; d-alpha-tocopheryl acid succinate, quantity: 41.32 mg; ascorbic acid, qua - capsule, hard - excipient ingredients: maltodextrin; calcium hydrogen phosphate; magnesium stearate; colloidal anhydrous silica; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; mono- and di- glycerides; starch sodium octenyl succinate; sodium ascorbate; dl-alpha-tocopherol; silicon dioxide; sucrose; medium chain triglycerides; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support energy levels ; helps convert (state food) into energy ; maintain/support energy production ; maintain/support healthy eye function ; maintain/support eye health ; maintain/support healthy eyesight/vision ; maintain/support general health and wellbeing ; maintain/support hair growth ; maintain/support connective tissue health ; aid/assist/helps connective tissue production/formation ; helps maintain/support transport of oxygen in the body ; aid/assist/helps oxygen transport to body tissues ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support muscle function ; maintain/support healthy neuromuscular system/function ; aid/assist/helps glucose/sugar/carbohydrate metabolism ; aid/assist/helps protein sy

Pharmacy Health Bone & Muscle Complex Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacy health bone & muscle complex

soul pattinson manufacturing pty ltd - heavy magnesium oxide, quantity: 83.5 mg (equivalent: magnesium, qty 50.36 mg); copper gluconate, quantity: 3.57 mg (equivalent: copper, qty 500 microgram); zinc amino acid chelate, quantity: 37.5 mg (equivalent: zinc, qty 7.5 mg); manganese amino acid chelate, quantity: 17.5 mg (equivalent: manganese, qty 1.75 mg); calcium carbonate, quantity: 1.5 g (equivalent: calcium, qty 600.6 mg); colecalciferol, quantity: 0.025 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose; maltodextrin; microcrystalline cellulose; crospovidone; acacia; titanium dioxide; macrogol 8000; maize starch; dl-alpha-tocopherol; silicon dioxide; sucrose; medium chain triglycerides - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support collagen formation ; maintain/support collagen health ; maintain/support energy production ; maintain/support healthy eye function ; maintain/support eye health ; maintain/support healthy eyesight/vision ; maintain/support general health and wellbeing ; maintain/support hair health ; maintain/support healthy teeth ; maintain/support nail health/strength/thickness ; maintain/support connective tissue health ; aid/assist/helps connective tissue production/formation ; maintain/support bone health ; aids/assists healthy bone development/growth/building ; maintain/support bone mass/density/integrity ; maintain/support bone strength ; help maintain/support bone mineralisation ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorpti

Sugammadex Pharmazac Solution for Injection 100mg/ml (2ml vial) Malta - English - Medicines Authority

sugammadex pharmazac solution for injection 100mg/ml (2ml vial)

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products